The Pet Vaccine Pharmaceutical Formulation unit at Carros (France) unveils its operations. 

The third portrait in our #ThankYouVetsAndFarmers series, Larry embodies the excellence of Irish farming, as well as the passion, hard work, and respect for the land that he passes on to his children.

At the heart of global aquaculture, tilapia health is a strategic issue. Opened in 2021, our Virbac Aquaculture Technology Center (VATC) in Vietnam is much more than a laboratory: it is our central platform in the fight against microbial diseases. With its cutting-edge diagnostic expertise and ISO 17025 certification, the VATC is the cornerstone of our vaccine strategy, translating raw data into concrete solutions that are essential to Virbac's growth and credibility across three major continents.

Find details of the 2025 fourth quarter consolidated sales

Discover the daily life of this inspiring mixed-practice veterinarian in rural France, the heroine of our second episode of the #ThankYouVetAndsFarmers series.

Watch the New Year’s greetings video from Paul Martingell.

Discover the world of a Thai aquaculturist in the first episode of our video portrait series #ThankYouVetsAndFarmers, dedicated to farm animal professionals across the globe.

Acquisition provides Virbac with a leading specialty product, in a growing segment, to improve the quality of life for senior cats.

Our new series of video portraits to pay tribute to veterinarians and farmers

Following its launch in the United States, Canada, and France, our Odyssey strategic program is reaching a decisive milestone with its global rollout. This new stage aims to gradually extend the benefits of this transformation to our subsidiaries, resulting in optimized business processes.

The growing number of pets in China, fueled by the rise of its middle class, is creating strong demand for veterinary products. To better meet this need, we have established a local manufacturing partnership. In September 2025, this collaboration led to our first production of a generic drug in the country.

Find details of the 2025 third quarter consolidated sales

Since August, our teams in France offer a new antiparasitic collar, protecting cats and dogs for up to 8 months from external parasites, addressing the global need to combat vector-borne diseases. In addition to ticks and fleas, it protects dogs against lice and reduces the risk of transmission of leishmania with indirect use on the vector. This new solution that supports continuum of care will progressively be available in other European countries, starting with Germany, Netherlands and Slovenia.

We are going to increase our vaccine production capacity with the construction of a new industrial site, Bio 5, in Carros (Alpes-Maritimes). This project, the foundation stone of which was laid on October 1st, is positioned as the Group's center of excellence for companion animal vaccines.

Starting September 2025, our teams will be offering Vikaly to European professionals and pet owners. This disruptive innovation, at the crossroads of our expertise in veterinary medicine and animal nutrition, foreshadows the emergence of a new therapeutic model, better adapted to daily constraints, aligned with contemporary veterinary practices, the expectations of pet owners, and animal welfare. Designed, developed, and manufactured in France, Vikaly demonstrates the commitment of our teams and our ability to open new paths in the management of companion animal health.

Find details of the 2025 half-year results

In July 2025, Suprelorin^® was granted marketing authorization in Japan. This product meets the needs of both veterinarians and pet owners for reversible and minimally invasive sterilization solutions.

Our team, responsible for drug registration and maintaining and defending Marketing Authorizations (MAs), is ready to reveal what they do.

In 2024, among our fourteen Great Place to Work^® certified subsidiaries, Virbac Mexico joined the Best Workplaces^® ranking, following in the footsteps of our UK and Colombia branches. This distinction reflects our commitment to creating inclusive, fulfilling, and trust-based work environments.

In the first half of 2025, revenue recorded solid growth of +5.6% at constant exchange rates and scope of consolidation

In the first half of 2025, revenue recorded solid growth of +5.6% at constant exchange rates and scope of consolidation

Because the biology professions are constantly evolving, we provide our teams with the highest level of skills in vaccine production. The Bio Academy, our in-house training centre, aims to integrate, develop and maintain these profiles at the cutting edge of technology and regulation.

Since the end of May, our Virbac teams in Thailand have achieved a decisive milestone for swine health. We now offer farmers two complementary oral vaccines specifically designed to prevent post-weaning diarrhea (PWD) and edema disease (ED) in piglets caused by F4 and F18 factors. These solutions enrich our global range and underscore our strong commitment to a preventive approach in livestock farming.

A cornerstone of our company's identification and differentiation, the Virbac logo is adapting to current standards.

Virbac Hellas is proud to celebrate the 20th anniversary of its presence in Greece. Over the past two decades, Virbac Hellas has established itself as a trusted partner for veterinarians, farmers, and pet owners, driven by a commitment to innovation, collaboration, and animal well-being.

Following a call for tenders from ENABEL, the Belgian development cooperation agency, we conducted a scoping study to optimize biosecurity and environmental practices in aquaculture in Rwanda. This project culminated in late 2024 with a reference document for the Rwandan government and fish farmers.

Virbac announces the appointment of Paul Martingell as the chief executive officer of the Virbac group, effective September 1, 2025.

Aware of the specific health challenges in each territory, we adapt our offerings to meet the needs of breeders and veterinarians. As of April 2025, our new combined vaccine against porcine parvovirus and leptospirosis is available in France, where both diseases pose significant health challenges.

Ten years after its launch, our Veterinary HPM^® physiological food range is being revamped and will be progressively rolled out, starting in Europe from May 2025, to better meet the changing expectations of veterinarians and pet owners. Our commitment, however, remains the same: to advance animal health through high-quality nutrition, based on science and innovation.

Launched a few months ago in around ten European countries, DIOD (Digital Interactive Otitis Drawings) is our new interactive digital tool. It allows for the modeling of all types of otitis, supporting explanations provided to pet owners and optimizing patient management. Developed by our teams, it further enriches our DailyDerma program, which assists with daily veterinary dermatology practice.